PCN24 ECONOMIC EVALUATION OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA- AN UPDATED COST-EFFECTIVENESS ANALYSIS
May 1, 2008, 00:00 AM
10.1016/S1098-3015(10)70202-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)70202-3/fulltext
Section Title :
Section Order :
850
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70202-3&doi=10.1016/S1098-3015(10)70202-3